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ABSTRACT Pulmonary arterial hypertension (PAH) is a debilitating disease that pervades all aspects of
a patient’s daily life. It is also increasingly acknowledged that the burden of PAH extends to older patients
and carers. Until recently, the adverse effect of disease symptoms on the physical, emotional and social
factors governing patient health-related quality of life (HRQoL) remained largely unrecognised. With a
shift in therapeutic objectives to longer term improvements and HRQoL benefits, clinical trials now
frequently include HRQoL measures as study end-points. Most HRQoL instruments used in patients with
PAH are generic or non-disease-specific questionnaires and therefore may not accurately capture PAH
disease burden. New PAH-specific HRQoL instruments currently undergoing validation include
emPHasis-10 and Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT; Actelion
Pharmaceuticals Ltd, Allschwil, Switzerland). Using various HRQoL measures, pharmacological therapies
have been shown to improve HRQoL in patients with PAH. Patients also derive HRQoL benefits from
nonpharmacological strategies, which include the emotional support provided by multidisciplinary care
and support groups that is fundamental to patient wellbeing. Looking to the future, validated PAH-specific
HRQoL instruments together with dedicated guidelines and procedures are essential to support the
translation of HRQoL scores to the clinic, thus enabling a holistic treatment approach to the management
of patients with PAH.
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Introduction
Pulmonary arterial hypertension (PAH), characterised by increased pulmonary vascular resistance and
arterial pressure, affects an estimated 15–60 per million of the population, and is more commonly
diagnosed in women [1–3]. PAH causes a range of nonspecific symptoms (including breathlessness,
fatigue, chest pain and weakness) [3, 4] and is associated with significant morbidity and mortality
triggered by the debilitating progressive nature of the disease, which eventually leads to right heart failure
and death [3, 5–8]. The effect of disease symptoms on the patient’s physical mobility and emotional state
adversely affects health-related quality of life (HRQoL) [9, 10]. Although pharmacological treatments for
PAH (endothelin receptor antagonists, soluble guanylate cyclase stimulators or phosphodiesterase-5
inhibitors (PDE-5i), and prostacyclin analogues) and lung transplantation are available to alleviate disease
symptoms and slow disease progression [3], treatment-related adverse events and the inconvenience and
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side-effects of some routes of drug administration (for example intravenous and subcutaneous delivery)
can negatively influence patients’ daily life [11].
For patients living with PAH, the disease can be hugely devastating and exert an adverse impact on all
aspects of life: physical, social and emotional [4, 11, 12]. However, despite the significant progress that has
been made in the development of new therapies for PAH in the past two decades, the impact the disease
has on patients’ HRQoL was less well understood until recently. This article reviews the burden of PAH
on patients and carers and outlines measures currently used to evaluate HRQoL. Management options for
improving HRQoL in patients with PAH, with a focus on available pharmacological and nonpharmacological
strategies, are also discussed.
The burden of PAH
PAH imposes a considerable burden on the patient by affecting all aspects of daily life that govern
HRQoL, from physical activity, general health and vitality to emotional and social functioning (figure 1)
[9, 12]. Furthermore, when PAH is associated with conditions such as systemic sclerosis, patients have to
contend with the additional HRQoL burden of the primary condition [12]. Overall, the debilitating impact
of PAH on HRQoL is clear when compared with other medical conditions, being at least as severe as
illnesses such as chronic obstructive pulmonary disease and renal failure (figure 1), and those conditions
well recognised as being severely debilitating and life-threatening such as spinal cord injury, interstitial
lung disease or treatment-resistant cancer [12–15].
In particular, the physical activity of many individuals is reported to be severely affected by PAH
symptoms of breathlessness, fatigue and lack of energy, which, in turn, restrict the completion of even the
smallest everyday tasks such as housework and food shopping [4]. With respect to specific physical
activities that are affected by the disease, the International Patient and Carer Report from the European
Pulmonary Hypertension Association (PHA) revealed that the majority (83%) of the 326 surveyed patients
with PAH experienced difficulty climbing stairs and almost all patients (97%) found that the disease
affected their participation in sports and exercise to some extent [4]. These European findings are
mirrored by qualitative reports from the Patient Voice survey (∼85 participants) initiated by the US Food
and Drug Administration (FDA), which found that commonly reported symptoms of breathlessness and
fatigue were similarly restrictive on the daily physical activities of patients [11]. Results from other studies
suggest that the reduced physical activity due to PAH, as identified in the European PHA and FDA
Patient Voice surveys [4, 11], has negative implications for long-term outcomes. A recent study used a
wrist-worn device (actigraph) to monitor the everyday physical performance of patients with PAH or
chronic thromboembolic pulmonary hypertension over a 2-week period who were then followed-up for































Highest and lowest results for PAH patients
FIGURE 1 Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life
(HRQoL) measures versus the normal population and other disease conditions [12–15]. COPD: chronic
obstructive pulmonary disease; SF-36: Medical Outcomes Study 36-item short form.
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prolonged nocturnal rest correlated with severe haemodynamic impairment, reduced transplantation-free
survival and overall poorer prognosis [7]. The study also demonstrated that daytime activity positively
correlated with HRQoL [7], which is consistent with observations that functional status is a stronger
determinant of HRQoL than haemodynamic values [12]. Thus, as would be expected, with disease
progression, the decline in physical function reduces HRQoL in patients with PAH [9, 12].
While the physical consequences of PAH are widely acknowledged, the psychological impact of PAH is
frequently overlooked by patients and clinicians [16, 17]. Feelings of social isolation are often expressed by
patients with PAH, who ascribe this to the fact that there are no overt signs of their condition (i.e. the
disease is not “visible”) and to a lack of understanding or knowledge about the disease in the community
and among their friends and family [4]. These feelings are particularly prominent among patients aged
<30 years [4], an age group for whom social interaction may be a particularly significant part of their daily
life. Aside from social isolation, the impact of PAH can be seen on broader aspects of psychological health.
In a study of 101 patients with PAH, almost half (48%) suffered from mild to extremely severe symptoms
of anxiety, and approximately one-third experienced depressive (32.6%) and stress (27.6%) symptoms [16].
An earlier report, claiming to be the first study to investigate the prevalence of psychiatric disorders in
patients with pulmonary hypertension (PH), identified a concomitant psychiatric disorder in more than
one-third (35.4%) of patients [17]. In the study population, major depressive disorder and panic disorders
were the most common psychiatric disorders [17]. Interestingly, the prevalence of major depressive
disorder and panic disorder increased with greater functional impairment in patients participating in the
study [17]. Among those patients with a psychiatric diagnosis, only 24% received psychiatric treatment,
most commonly psychopharmacological medications [17]. Despite such studies, the association between
PAH and comorbid psychological symptoms (e.g. depression) continues to be under-recognised, as does
the impact of these symptoms on the HRQoL of patients with PAH [6, 16].
In an attempt to address this evidence gap, a recent study examined the prevalence of psychological
symptoms and their association with HRQoL in patients with PAH. The researchers noted that depressive
symptoms, together with functional class and disability, had a major impact on the observed variance in
HRQoL values among the study population [16].
Not only are there physical and psychological consequences for patients with PAH, employment is also
adversely affected by the disease and can lead to a significant reduction in household income [4]. In the
European PHA survey, 85% of participating patients reported that their work was affected by the disease
[4]. Of the 48% of patients who had to give up work or needed help in order to maintain employment,
most (73%) experienced a loss in average household income, with one in six reporting that their
household income had more than halved [4]. In addition, more than one-third (35%) of carers reported a
reduction in income because of a decrease in work hours or having to give up work completely to care for
their relative with PAH [4].
While surveys such as the European PHA and US Patient Voice reports have highlighted the significant
impact of PAH on the general population of patients [4, 11], there is growing recognition among clinicians
that the burden of PAH may be particularly significant among older populations [1]. PAH is increasing in
prevalence in patients aged 50–65 years, who are more likely to be diagnosed in advanced stages of the
disease (World Health Organization functional class (WHO FC) III/IV), have lower exercise capacity and a
greater comorbidity burden [1]. Comorbid ischaemic heart disease, coronary artery disease, hypertension,
atrial fibrillation, diabetes and hypothyroidism have all been reported at higher rates in patients with PAH
aged >50 years compared with younger patients [1, 18]. The presence of multiple comorbidities often leads
to a delay in the diagnosis of PAH in older patients, which may account for the relatively low level of
disease recognition in this population in earlier years [1]. This higher comorbidity burden may also
contribute to the poorer survival rates seen among a cohort of newly diagnosed older patients in the UK
and Ireland who were three-fold more likely to die versus their younger counterparts (⩽50 years of age);
the latter group had fewer comorbidities and better functional and exercise capacity [19].
Women with PAH of child-bearing age face the additional burden of a significantly increased risk of
complications during pregnancy as a result of their poor tolerance of the associated haemodynamic and
physiological changes, which can lead to right ventricle failure and arrhythmias [20]. Pregnancy is
associated with a substantial mortality rate in PAH [21], although there has been evidence to show that
survival among pregnant women with PAH has improved over the past few decades [22]. Nevertheless, it
is recommended that patients with PAH avoid pregnancy [3]. The contraindication for pregnancy can
have a detrimental effect on family life for patients with PAH [23], and the fear of becoming pregnant can
also have a negative impact on patients’ relationships with their partners [4].
The burden of PAH not only affects the patients, but also extends to their carers [4]. Until studies such as
the European PHA and US FDA Patient Voice surveys were conducted, research on the impact of PAH on
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patient life was scarce [4, 11]. Therefore, it is unsurprising that there is a similar lack of research regarding
the effect of PAH on carers, a role often taken by the patient’s partner or family members [4]. The
aforementioned European PHA survey, in addition to patients, included 129 carers whose relationship to
the patient (not necessarily a patient included in the survey) was either as a spouse or partner (55%),
parent (21%), child (18%), family member (5%) or friend (1%) [4]. More than half (57%) of carers
reported a very high impact (rating of 8–10 on a scale of 10) from the patient’s PAH on their own daily
lives, with the proportion of carers experiencing this level of impact on their life increasing as the patient’s
functional status declined (41%, 53% and 88% of those caring for a patient with WHO FC II, III and IV,
respectively). A significant proportion of carers (43%) found the extra tasks and responsibilities associated
with the patient’s condition physically exhausting [4]. Moreover, feelings of social isolation and disrupted
sexual relationships experienced by patients were also reported by carers, in addition to other changes in
carers’ emotional and social wellbeing [4]. A further caregiver study noted the perceived lack of social
support reported by a surveyed population of 35 carers of patients with PAH [24]. The study also found a
significant association between lower levels of social support and greater severity of depressive symptoms
in carers [24]. On a positive note, the overwhelming majority (92%) of carers in the European PHA survey
felt that they were helping to improve the patient’s HRQoL [4].
For patients with PAH, and by extension their carers, pharmacological treatments form the mainstay of
disease management. However, invasive, cumbersome and painful routes of administration for some
treatments (e.g. parenteral, subcutaneous or inhaled prostacyclin therapy) and side-effects of therapy can
adversely affect treatment acceptance and HRQoL in patients with PAH [11, 25–28]. As reported by
participants in the FDA Patient Voice survey, daily life is significantly affected by the burden of living with
an intravenous line, while the complexity and inconvenience of some drug regimens can be difficult to
incorporate into everyday life [11].
Additionally, intolerable side-effects such as site infections from intravenous lines or the pain of
subcutaneous treatment were cited in the Patient Voice survey as reasons for poor treatment acceptance
and changes in treatment [11]. The requirement for oxygen therapy is also associated with poor HRQoL
[9]. Although patients can adjust to oxygen use, adherence can be affected by the patient’s perception of
the interference caused by the restrictions of oxygen dependence [9]. The development of oral
formulations of PAH therapies (such as endothelin receptor antagonists, PDE-5i and prostacyclin
analogues) and a room temperature stable intravenous formulation of epoprostenol containing arginine
and sucrose may improve treatment acceptance through greater convenience, compared with existing
intravenous formulations [28–31].
Overview of HRQoL questionnaires
As the number of PAH treatment options has expanded, clinical outcomes have improved beyond
short-term functional and symptomatic benefits. Therefore, the objectives of therapy are now focused on
longer term improvements and beneficial effects on HRQoL [25, 32]. Consequently, measurement of
HRQoL is increasingly incorporated within the design of PAH clinical trials as a secondary or exploratory
end-point [25]. HRQoL measures fall within the category of health status measures defined as
patient-reported outcomes (PROs), which refer to measurements that are directly obtained from the
patient without influence or the interpretation of response from others [33, 34]. The use of PRO
instruments is advocated to assess specific variables that are best known by the patient or best measured
from the patient’s perspective (for example, symptoms or their impact) [34].
Various HRQoL instruments have been employed to measure the effects of PAH on patients’ daily lives, the
majority of which are generic or non-PAH-specific measures (table 1) [33, 35–41]. HRQoL assessments are
administered in the form of a questionnaire, but there are inherent differences between scales, including the
length of the questionnaire and health domains evaluated (table 1). Furthermore, depending on the HRQoL
scale, a higher score can be indicative of either better or worse HRQoL (figure 2). HRQoL validity analyses
suggest that existing generic scales are not wholly ideal for use in patients with PAH. For example, the
Medical Outcomes Study 36-item short form (SF-36) and the Minnesota Living with Heart Failure
Questionnaire correlate poorly with haemodynamic measurements [33], which emphasises the fact that
non-PAH-specific instruments may not accurately capture the PAH burden and may be less sensitive to
change in HRQoL with treatment [25].
A growing understanding of the limitations of existing HRQoL scales, together with the need for
standardisation of HRQoL measures in PAH, has focused research efforts towards developing and
validating PAH-specific instruments. At present, Cambridge Pulmonary Hypertension Outcome Review
(CAMPHOR) represents the only validated questionnaire for evaluation of HRQoL in patients with PH
[42], but the questionnaire may have limited application in routine clinical practice given its length (65
items), cost, and the fact that it has only been validated for 11 languages [43]. Furthermore, despite its focus
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on the PH population, CAMPHOR may not accurately encapsulate all the key PAH symptoms [40, 42].
Accordingly, researchers have placed greater emphasis on designing a simple, rapidly administered
disease-specific questionnaire that is easy to use in clinical practice for evaluation of HRQoL in patients
with PAH [42]. The PAH-specific PRO instrument Pulmonary Arterial Hypertension-Symptoms and
Impact (PAH-SYMPACT; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland) questionnaire to assess
PAH symptoms and their impact on patients’ lives is currently being developed in accordance with the US
FDA guidance on PRO development [44]. Based on qualitative research in patients with PAH, a draft
conceptual framework for the PAH-SYMPACT questionnaire was developed, encompassing four symptom
domains (respiratory symptoms, tiredness, cardiovascular symptoms and other symptoms) and five impact
domains (physical activities, daily activities, social impact, cognition and emotional impact) [44]. The
PAH-SYMPACT tool is currently undergoing final content and psychometric validation in phase 3b,
prospective, single-arm, open-label studies in patients with PAH in the USA (SYMPHONY; NCT01841762)
and Europe (ORCHESTRA; NCT02081690) [44–46]. Another recently proposed PAH-specific tool is
emPHasis-10, a 10-item questionnaire, which in a qualitative study of 226 patients with PH (82% of whom
had PAH) was reported to demonstrate sensitivity to clinical parameters relevant to PAH, such as change
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FIGURE 2 Scoring system for health-related quality of life (HRQoL) scales [33, 40]. SF-36: Medical Outcomes
Study 36-item short form; EQ-5D: EuroQol Group 5-Dimension Self-Report Questionnaire; NHP: Nottingham
Health Profile; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; MLHFQ: Minnesota Living
with Heart Failure Questionnaire; LPH: Living with Pulmonary Hypertension questionnaire; CHQ: Chronic
Heart Failure Questionnaire.
TABLE 1 Summary of health-related quality of life scales used in pulmonary arterial hypertension
Scale Domains Items n Recall period
Generic
SF-36 [35] 8 domains: physical functioning, role physical, bodily pain, general health,
vitality, social functioning, role emotional, mental health
36 Now to past 4 weeks
EQ-5D [36] 5 domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression 5 Today
NHP [37] 6 domains: physical mobility, pain, social isolation,
emotional reactions, energy level, sleep
38 At the moment
Disease-specific
CAMPHOR [38] 3 domains: overall symptoms (energy, breathlessness, mood),
functioning, quality of life
65 Today
MLHFQ [39] 2 domains: physical, emotional 21 4 weeks
LPH# [40] 2 domains: physical, emotional 21 1 week
CHQ [41] 4 domains: dyspnoea, fatigue, emotional function, mastery 20 2 weeks
emPHasis-10 [42] Unidimensional 10 At the moment
SF-36: Medical Outcomes Study 36-item short form; EQ-5D: EuroQol Group 5-Dimension Self-Report Questionnaire; NHP: Nottingham Health
Profile; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; MLHFQ: Minnesota Living with Heart Failure Questionnaire; LPH:
Living with Pulmonary Hypertension questionnaire; CHQ: Chronic Heart Failure Questionnaire. #: adapted from MLHFQ. Information from [25, 33].
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PAH management: improving HRQoL
Clinical studies have shown that PAH therapies improve HRQoL in patients with PAH [47–57]. In these
studies, various scales were employed to evaluate change in HRQoL, which limits comparisons between
studies [33]. Nevertheless, the SF-36 (alone or in combination with the EuroQol Group 5-Dimension
Self-Report Questionnaire (EQ-5D)) was the most commonly used measure across trials [25, 58]. Early
studies of PDE-5i, Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) and Sildenafil
Use in Pulmonary Arterial Hypertension 1 (SUPER-1), measured change in HRQoL for ⩽24 weeks of
treatment in patients with PAH via the SF-36 and EQ-5D [55, 56]. Results from these two studies reported
significant improvements in six of eight SF-36 domains and EQ-5D scores with tadalafil (p<0.05), while
physical functioning, vitality and general health domains, and the EQ-5D health status and utility
index scores were significantly improved in patients who received sildenafil (p<0.05) [55, 56]. In the
Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled,
Multicenter, Efficacy Study (ARIES)-1, the endothelin receptor antagonist ambrisentan was associated with
significant improvement in the SF-36 physical functioning domain at 12 weeks (p=0.005), whereas a trend
towards improvement in SF-36-measured health domains did not reach statistical significance in ARIES-2
[47]. More recently, the long-term Study with an Endothelin Receptor Antagonist in Pulmonary Arterial
Hypertension to Improve Clinical Outcome (SERAPHIN) trial showed that macitentan significantly
improved seven of eight health domains and both the physical and mental component summary scores of
the SF-36 at month 6 (p<0.05) [50]. Given the treatment-related benefits in HRQoL observed in patients
with PAH, mounting evidence implicates a future role for improved HRQoL as a prognostic marker in
PAH [59]. In a study of 54 consecutive newly diagnosed patients with PAH who received first-line
endothelin receptor antagonists or PDE-5i, a baseline SF-36 Physical Component Summary (PCS) score
>32 was associated with a better survival rate than a score <32 (p=0.04). Moreover, patients exhibiting a
PCS score ⩾38 after 16 weeks of treatment demonstrated superior 3-year survival rates versus those who
scored <38 on the PCS (p=0.016) [59].
In addition to these PAH-targeted pharmacological treatments, agents used for the management of
concomitant conditions (e.g. for depression or poor sleep quality) play an essential role in improving
patient comfort, which, in turn, has the potential to exert a significant positive impact on HRQoL [60].
Furthermore, nonpharmacological strategies such as exercise training and palliative care can prove
beneficial for improving HRQoL in patients with PAH [10, 61–63]. Symptoms of PAH that affect physical
function have a negative impact on HRQoL [10]. It follows, therefore, that improvements in physical
fitness and function through exercise rehabilitation can positively affect patient HRQoL [10]. Indeed, some
clinical evidence supports the beneficial effects of exercise training on patient HRQoL in addition to
increases in aerobic capacity, muscle strength and exercise tolerance [61]. However, further studies are
necessary to conclusively support this finding [10].
Although palliative care, such as end-of-life management by a multidisciplinary healthcare team and/or
hospice referral, is another nonpharmacological strategy that may confer significant HRQoL benefits to
patients, surveys suggest that patients may be unaware of, or are not offered, the opportunity to explore
this option [62–64].
Other nonpharmacological interventions may serve an important purpose in providing the emotional
support that has been shown to be fundamental to the wellbeing of patients with PAH and their families
[4]. Accordingly, the adequate provision of psychosocial support has undergone close scrutiny by
professional organisations. In their recent guidance, the joint task force of the European Society of
Cardiology (ESC) and the European Respiratory Society (ERS) issued a level I-C recommendation
(recommended/indicated based on expert opinion and/or observational studies and registries) for patients
to receive psychosocial support [3], reflecting the importance of this approach for improving HRQoL.
Furthermore, the task force advised that patients and their families should be encouraged to join patient
support groups. These organisations can have an important role in helping patients cope with their PAH
and can improve their confidence and outlook on life [3]. The ESC/ERS guidelines state that
multidisciplinary teams should be involved in the delivery of psychosocial support, so that the
psychological, social, financial, emotional and spiritual needs of patients can be managed effectively [3]. In
this respect, the multidisciplinary team can perform a vital role in assuming responsibility for the
evaluation of patient HRQoL and translation of these results into clinical practice [65]. Ultimately, in
attempting to delineate and reduce the burden of PAH on the patient, it is important to understand that
physician and patient expectations from disease management are likely to differ [58].
Conclusions
The considerable burden of PAH and its impact on the HRQoL of both patients and their carers is
becoming increasingly recognised. It is encouraging that recognition of the importance of patient quality of
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life is assuming prominence in the clinical setting in terms of greater emphasis on practice
recommendations and implementation of HRQoL measures to evaluate treatment effectiveness.
Nevertheless, areas of uncertainty remain, primarily the need for guidelines and procedures to support the
translation of HRQoL scores to the clinic. Further developments should focus on the assessment of HRQoL
based on validated PAH-specific PRO instruments, which is essential to gauge the impact of the disease on
patients’ HRQoL and thus facilitate a step towards better holistic treatment of patients with PAH.
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